The European Hematology Association (EHA)

CAR T cells are generating impressive outcomes in acute lymphoblastic leukemia (ALL) and other hematologic malignancies. This session highlights data regarding this novel approach, as well as improved methods for prognosticating patient outcomes using minimal residual disease findings. Read More ›

Immuno-oncology agents, particularly checkpoint inhibitors, are altering treatment paradigms in multiple solid and liquid tumors. Nivolumab (NIVO) was recently indicated for use in patients with relapsed Hodgkin lymphoma, representing the first approval of checkpoint inhibitors in a hematologic malignancy. Researchers report early but intriguing findings regarding use of NIVO and 5-azacitidine in adults with relapsed acute myeloid leukemia (AML).

Read More ›

Venetoclax, a selective oral BCL-2 inhibitor, is approved in the United States for use in patients with high-risk chronic lymphocytic leukemia (CLL) after 1 prior therapy. Studies evaluating the role of venetoclax in combination with anti-CD20 antibodies and other agents used for CLL represent the next step in the agent’s evolution. Using post hoc analysis, this study compares outcomes associated with venetoclax monotherapy to venetoclax combined with rituximab in relapsed CLL.

Read More ›

Ibrutinib, the first commercialized inhibitor of Bruton’s tyrosine kinase, is now approved for first-line use in patients with chronic lymphocytic leukemia. Because patients enrolled in clinical trials, as well as the level of monitoring in trials, do not always reflect community-based oncology practice, it is critical to evaluate data from large patient registries to learn if outcomes are reproducible in the real world.

Read More ›

Outcomes in patients with chronic myeloid leukemia (CML) have significantly improved after the introduction of tyrosine kinase inhibitors (TKIs). To facilitate discrimination of patients’ probability of dying of CML or other causes, the European LeukemiaNet recently published a new scoring system, EUTOS long-term survival (ELTS). This score was based on CML patients who were initially treated with imatinib. Researchers report findings from a study that evaluated the prognostic value of ELTS score in CML patients who were treated with nilotinib, a second-generation TKI. Read More ›

A large phase 3 trial compared blinatumomab, a bispecific CD19-directed CD3 T-cell engager (BiTE®) antibody construct, with standard-of-care chemotherapy regimens in adults with relapsed or refractory Philadelphia-negative B-cell precursor acute lymphoblastic leukemia (ALL).

Read More ›

Developments in chronic lymphocytic leukemia (CLL) continue to move at a rapid pace. New agents show deep and durable responses in relapsed and treatment-naïve patients. This session includes reports of large clinical trials that demonstrate durable activity and safety of targeted agents for CLL. Read More ›

Allogeneic hematopoietic stem-cell transplantation (alloHSCT) is a potentially curable treatment modality for adults with acute lymphoblastic leukemia (ALL), offering significant improvement in survival and reduction in relapse incidence. This approach is limited, however, by toxicity and early mortality. Researchers report outcomes of patients who received RIC followed by alloHSCT in the UKALL14 trial. Read More ›

Treatment options for acute myeloid leukemia (AML) in patients aged >60 years include intensive chemotherapy (IC) and azacitidine (AZA). The multicenter RAS-AZIC study of the East German Study Group (OSHO), evaluated first-line treatment with AZA followed by AZA or IC in these patients. Data from the planned interim analysis are presented. Read More ›